In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Out Of The Blocks, January 2015

Executive Summary

Snapshots of these recently formed companies: Aspen Park Pharmaceuticals, CeMeT, Enlitic, Prima-Temp, and TC BioPharm.

Aspen Park Pharmaceuticals Inc.

944 Park Avenue

New York, NY 10028

Phone: (901) 581-5872

Email: [email protected]

Management: Mitchell Steiner, MD, Co-founder, President & CEO; Harry Fisch, MD, Co-founder, Chairman & CSO

Company Launched: October 2014

Financing To Date: Undisclosed Series A

Investors: Undisclosed

Partners/Alliances: NA

Industry Segment: Men’s Health

Business: Aspen will develop therapeutics for a variety of men’s health conditions including male secondary hypogonadism, prostate cancer, and sexual dysfunction. It’s in late-stage trials of a novel form of clomiphene citrate to treat men with hypogonadism, and also has an OTC product, Preboost, a topical benzocaine wipe to treat premature ejaculation.

[CeMeT GMBH]

Paul-Ehrlich-Strasse 23

72076 Tübingen, Germany

Phone: +49 7071 565 44 460

Email: [email protected]

Web Site: www.cemet-gmbh.de

Management: Dirk Biskup, PhD, Managing Director; Isabell Flade, Director; Ingo Autenrieth, PhD, Daniel Huson, PhD, and Detlefn Weigeln, PhD, Scientific Founders & Advisors

Company Launched: July 2014

Financing To Date: Undisclosed

Investors: Undisclosed

Partners/Alliances: CeGat GMBH; Max-Planck Institute; University of Tübingen; University Hospital of Tübingen

Industry Segment: Metagenomics

Business: Founded by genetic diagnostics company CeGaT GMBH and three Tubingen-area academics, CeMeT’s mission is to analyze the genetic information of microorganisms in the human body and advance development of diagnostics and treatments. The company offers its metagenome analysis services to doctors and scientists, as well as private clients.

[Enlitic Inc.]

1355 Market Street

Suite 488 San Francisco, CA 94103

Email:[email protected]

Web Site: www.enlitic.com

Management: Jeremy Howard, Founder & CEO; Ahna Girshick, PhD, Choon Hui Teo, PhD, and John Zedlewski, Senior Data Scientists; Rodney Sappington, PhD, Senior Clinical Data Scientist

Company Launched: July 2014

Financing To Date: $2 million seed funding

Investors: Amplify; Data Collective

Partners/Alliances: NA

Industry Segment: Big Data

Business: Enlitic will use deep learning to mine and process data from medical images, giving doctors a tool to discover subtle patterns that characterize disease profiles and guide their diagnoses.

Prima-Temp Inc.

2820 Wilderness Place

Suite C

Boulder, Colorado 80301

Email: [email protected]

Web Site: www.prima-temp.com

Management: Lauren Costantini, PhD, CEO; Wade Webster, MD, Co-founder & CMO; Rich Pollack, Co-founder & CTO; Don Kirkpatrick, Chairman

Company Launched: September 2013

Financing To Date: Undisclosed

Investors: Undisclosed

Partners/Alliances: NA

Industry Segment: Wearable Sensors

Business: Prima-Temp’s self-inserted cervical ring contains a sensor that tracks body temperature, helping women identify times of peak fertility.

TC BioPharm Ltd.

Pentlands Science Park

Bush Loan

Edinburgh, EH26 0PZ, Scotland

Phone: +44 131 445 6197

Email: [email protected]

Web Site: www.tcbiopharm.com

Management: Michael Leek, PhD, CEO; Artin Moussavi, PhD, Executive Chairman; Angela Scott, Operations Director; Keith Gillon, PhD, Director of Clinical & Regulatory Affairs; David Gallagher, Director of Commercial Affairs

Company Launched: July 2013

Financing To Date: Undisclosed

Investors: Medinet; Other undisclosed investors

Partners/Alliances: Medinet; Sistemic

Industry Segment: Regenerative Medicine

Business: TC BioPharm is developing an autologous anti-cancer immunotherapy that involves expansion of naturally occurring, cancer-killing T cells over several weeks, formulating a treatment for a wide variety of different tumor types. The start-up recently opened a clinical manufacturing facility in Glasgow.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

IV004297

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel